Computational scan of public-domain patent and patent-application disclosures across the chemistry, mechanism, and delivery axes surfaced by WP1–WP5. Identifies open claim space and FTO landmines for the recommended retina-first program and the KAT8 long-bet.
The KAT8/MOF axis is the cleanest filable white space identified by RIA-01. The combination architecture (priming chemistry + AAV-OSK pulse + maintenance chemistry) is filable as a method-of-use claim even where individual components are heavily patented. Tazemetostat composition claims are locked by Epizyme, but reprogramming-specific method-of-use claims for Tazemetostat have not been disclosed to RIA-01's search date.
Cross-walks cleanly into Atlas Bio's existing IP base — U.S. Provisional 63/986,270 (filed Feb 19, 2026, capsid intelligence platform). A second provisional cluster on the reprogramming methodology is the recommended path for counsel evaluation.
RIA-01 surveyed public-domain patent disclosures via Google Patents, USPTO PAIR, EPO Espacenet, and WIPO PATENTSCOPE indices using keyword combinations: "MOF" / "KAT8" / "MYST1" + "small molecule"; "H4K16ac" + "aging"; "partial reprogramming" + method; "Yamanaka factor" + "AAV"; "Tazemetostat" + "epigenetic"; "tet enzyme" + "reprogramming"; "epigenetic clock" + "reversal". The search is intentionally surface-level and excludes Chinese-language filings, machine-translated regional applications, and recently-filed applications under 18-month publication delay.
| Patent family (representative) | Assignee | Scope | Status for Atlas Bio |
|---|---|---|---|
| JP / WO Yamanaka factor base patents (~2006–2008 priority) | Kyoto Univ / iPS Academia Japan | OSKM and OSK factor combinations; methods to induce pluripotency from somatic cells | CROWDED |
| Partial reprogramming / cyclic factor exposure | Salk Institute (Belmonte) | In vivo cyclic OSKM in progeria and aged-mouse models | CROWDED |
| Reprogramming with reduced factor count (OSK no MYC) | Multiple academic + biotech | Various method claims around OSK without c-MYC | PARTIAL (method-of-use new combinations may be open) |
| mRNA-based transient reprogramming (OSKMLN) | Stanford / Sebastiano-affiliated | Transient mRNA delivery for aging-related cell improvement | CROWDED for mRNA path |
| Patent family | Assignee | Scope | Status |
|---|---|---|---|
| AAV-delivered OSK for retinal rejuvenation | Harvard / Sinclair-affiliated entities | AAV-OSK to retinal ganglion cells; vision restoration methods (per Lu 2020 lineage) | CROWDED for retina-specific OSK delivery |
| AAV9 capsid composition claims | UPenn (Wilson lab) / Penn Vector Core | AAV9 serotype composition and use | CROWDED — license required for commercial use |
| PHP.eB and BBB-capable engineered capsids | Caltech (Gradinaru / Deverman labs); Broad | Engineered AAV capsids for CNS transduction | CROWDED — license/collaboration required |
| 4D-R100 / 4D-C102 engineered capsids | 4D Molecular Therapeutics | Engineered capsid composition + clinical use | CROWDED — partnership/license required |
| Re-dosable AAV / immune-evading surface mods | Various academic + biotech; emerging | Engineered capsid surface modifications for NAb evasion | PARTIAL — emerging field, white space possible |
| Patent family | Assignee | Scope | Status |
|---|---|---|---|
| KAT6A/KAT6B selective inhibitors (PF-9363, WM-1119, CTx-648) | Pfizer / Cancer Therapeutics CRC | KAT6 inhibitor composition + cancer use | CROWDED but oncology-only; KAT6 selectivity excludes KAT8 |
| Tip60 / KAT5 inhibitors (MG-149, anacardic acid analogs) | Academic; SGC tool compounds | Composition + research-use claims | PARTIAL — mostly tool-compound publications, fewer composition claims |
| KAT8 / MOF selective activator | NONE IDENTIFIED | — | OPEN — no clean prior art |
| NSL complex modulators / KANSL1-MCRS1 PPI | Largely academic; no biotech filings identified | — | OPEN |
| MSL complex stabilizers (MSL1/2/3-MOF interaction) | Academic only | — | OPEN |
| H4K16ac restoration methods for aging | Patchy academic; no biotech method-of-use franchise | — | OPEN — method-of-use white space |
| Patent family | Assignee | Scope | Status |
|---|---|---|---|
| Tazemetostat (EPZ-6438) composition | Epizyme (now Ipsen) | EPZ-6438 chemical composition; method-of-use in EZH2-mutant lymphoma and epithelioid sarcoma | CROWDED — composition locked; oncology use locked |
| GSK126, EPZ-6438 second-gen analogs | GSK / Epizyme | Composition + cancer use | CROWDED for composition |
| Tazemetostat / EZH2-i method-of-use in partial reprogramming / aging | NONE IDENTIFIED | — | OPEN — reprogramming-specific use claims appear unclaimed |
| EZH2-i + AAV-OSK combination methods | NONE IDENTIFIED | — | OPEN |
| Patent family | Assignee | Scope | Status |
|---|---|---|---|
| Vitamin C in iPSC reprogramming (Esteban 2010 era) | Various academic; some biotech disclosures | Method-of-use of vitamin C to enhance reprogramming efficiency | PARTIAL — broad iPSC use claimed; partial reprogramming use less explicitly claimed |
| α-KG / 2-OG supplementation methods | Various | Metabolic / longevity supplementation | PARTIAL |
| Vit C + α-KG combination priming in partial reprogramming + AAV-OSK | NONE IDENTIFIED | — | OPEN as a specific combination method-of-use |
| Patent family | Assignee | Scope | Status |
|---|---|---|---|
| Horvath multi-tissue clock | UCLA | DNA methylation-based age estimation methods | CROWDED — commercial use requires license |
| GrimAge, PhenoAge clocks | UCLA / Levine, Horvath | Mortality-trained clock composition | CROWDED |
| DunedinPACE | Duke / Belsky-affiliated | Pace-of-aging clock | CROWDED for clock itself; open for clinical-trial endpoint use methods |
| CausAge / causal clock framework | Sinclair-affiliated; newer | Causal CpG filtering methodology | PARTIAL — emerging IP |
| Use of aging clocks as endpoints in partial-reprogramming trials | NONE IDENTIFIED (likely too narrow to file alone) | — | PARTIAL — combination-method possible but narrow |
David Sinclair (Harvard) and affiliated entities (Life Biosciences, Iduna Therapeutics, Tally Health) hold a substantial patent cluster across aging-clock methodology, OSK delivery for vision, and chemical reprogramming. RIA-01 surfaces this as a meta-landscape factor: any Atlas Bio program in the retina-first or aging-clock space should anticipate proximity to Sinclair-cluster filings. Counsel-led patent-family-pendency check is essential.
Two visualizations of the patent landscape. The quadrant chart positions each opportunity by strategic value (Y) and patent density (X). The density bar chart ranks each technical lane by how crowded the IP space is.
Density % is RIA-01's qualitative estimate of how crowded each lane is with filed-and-issued patents plus published applications. The top six lanes (KAT8 activator, NSL/MSL stabilizers, H4K16ac restoration methods, Tazemetostat reprogramming use, EZH2-i+OSK combinations, 3-phase architecture) are the principal P0/P1 filable targets — bundled into Cluster A–C in section 5 below.
| Opportunity | Claim type | White-space confidence | Urgency | Counsel priority |
|---|---|---|---|---|
| Novel KAT8 / MOF small-molecule activator chemotype | Composition of matter | HIGH (no prior art identified) | High (defensible long-bet IP) | P0 Counsel review |
| NSL / MSL complex stabilizer chemotypes (Strategy 1 deliverables) | Composition + method of use | HIGH | Medium (dependent on WP2.1 program output) | P1 |
| Method-of-use for Tazemetostat in partial-reprogramming maintenance | Method of use | MEDIUM–HIGH | HIGH (Epizyme/Ipsen could also file) | P0 Counsel review |
| Vit C + α-KG combination priming for AAV-OSK reprogramming | Method of use (combination) | MEDIUM | Medium | P1 |
| Three-phase architecture: priming + AAV-OSK + maintenance (the retina-first program) | Method of use (combination architecture) | MEDIUM (combinations are filable even with crowded individual components) | HIGH (the program-defining IP) | P0 Counsel review |
| Re-dosable / immune-evading engineered AAV variant for cyclic OSK delivery | Composition + method of use | MEDIUM | Medium (cross-walks to existing 63/986,270) | P1 |
| H4K16ac restoration as a measured endpoint in reprogramming trials | Method (assay use) | LOW (likely too narrow to file alone) | Low | P2 |
| RIA-01 itself: AI agent for computational reprogramming research | Method / software (jurisdiction-dependent) | LOW (software patentability varies) | Low | P2 |
Counsel priority is RIA-01's directional flag, NOT a filing instruction. P0 = recommend counsel review within 30 days. P1 = within 90 days. P2 = within next budget cycle.
Composition-of-matter claims on KAT8 activators or NSL/MSL complex stabilizers (when WP2.1 Strategy 1 produces a tool); method-of-use claims for H4K16ac restoration in retina, CNS, and other tissue-targeted reprogramming contexts; combination claims with AAV-OSK delivery. Timing: ideally before any public disclosure of the WP-final white paper.
Combination method-of-use covering the priming → pulse → maintenance architecture; specific Vit C + α-KG → AAV-OSK → Tazemetostat combination claims; tissue-restricted retina/CNS embodiments. Timing: before publication of the retina-first program design.
Method-of-use claims for Tazemetostat (and selective EZH2-i more broadly) specifically in cyclic / pulsed reprogramming maintenance; combinations with OSK delivery; dose schedules separate from approved oncology use. Timing-sensitive: Epizyme/Ipsen could also file in this space.
Continuation-in-part or new provisional extending Atlas Bio's existing capsid intelligence platform IP into surface-modified, immune-evading variants suitable for cyclic delivery. Natural extension of 63/986,270. Timing: coordinate with existing patent prosecution.
Software / method claims on the AI-agent scoring methodology. Jurisdiction-dependent (US software patentability post-Alice; EU software patent restrictions). May be more appropriate as trade secret + copyright on the agent prime directive than as patent. Counsel call.
| Component | Blocking IP holder | Mitigation path |
|---|---|---|
| 4D-R100 retinal capsid | 4D Molecular Therapeutics | Partnership / license / co-development — same path as the existing 4DMT case study |
| AAV9 serotype | UPenn / Penn Vector Core | Standard AAV9 license terms; commercial use defined |
| PHP.eB engineered capsid | Caltech (Gradinaru / Deverman) | License or substitute with platform-derived BBB-capable variant from Atlas Bio's existing engineering pipeline |
| Tazemetostat composition | Epizyme / Ipsen | License required for commercial use; off-label investigator-initiated study path; alternatively use a GSK126 or other selective EZH2-i if separable IP path |
| OSK / OSKM factors | Kyoto Univ / iPS Academia Japan; multiple later filings | Reduced-factor cassettes (OS only; or OSK with specific stoichiometries) may be filable around base patents; counsel review |
| Aging-clock methods (Horvath, GrimAge, DunedinPACE) | UCLA; Duke | Commercial license for endpoint use in trials; some clocks have research-use exceptions |
| AAV-OSK retinal delivery method | Harvard / Sinclair-affiliated | Hardest landmine. Combination embodiments with the priming + maintenance layers may distinguish; counsel-led claim chart essential |
| Element | Status in 63/986,270 | WP7 recommendation |
|---|---|---|
| AAV capsid intelligence platform (scoring methodology) | Covered | No action; continue prosecution |
| BBB-capable capsid scoring (PHP.eB, AAV9, 4D-R100/C102) | Covered | No action |
| Reduced humoral-immunity capsid engineering | Likely not explicitly covered | Consider continuation-in-part (Cluster D) |
| Reprogramming-specific method-of-use claims for capsid platform | Probably not covered | Consider Cluster B as a separate provisional referencing 63/986,270 as a related application |
| KAT8 / H4K16ac restoration methods | Almost certainly not covered (different mechanistic axis) | Cluster A is a new family |
| Tazemetostat method-of-use | Not covered | Cluster C is a new family |
The single most important timing principle for the WP-final synthesis and any subsequent publications: